Amisulpride - Acacia Pharma

Drug Profile

Amisulpride - Acacia Pharma

Alternative Names: APD-403; APD-421

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Acacia Pharma
  • Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative nausea and vomiting
  • Phase II Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Aug 2016 Acacia Pharma completes a phase I pharmacokinetics trial in Healthy volunteers in Netherlands (IV) (NCT02881840)
  • 12 Aug 2016 Acacia Pharma has patent protection for amisulpride usage
  • 12 Aug 2016 Interim efficacy data from a phase III trial in Post-operative nausea and vomiting released by Acacia Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top